Cellectar Biosciences (NASDAQ:CLRB – Free Report) had its price target lifted by Roth Mkm from $20.00 to $28.00 in a research note published on Thursday morning, Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. CLRB has been the subject of a number of other research reports. StockNews.com upgraded Cellectar […]